Rescreening to confirm the phenotypes of selected mutants was performed by spotting corresponding disruption mutants from the BY4742 genetic background on standard agar plates as described in the spotting assay above
31, 2025, policy change that revoked GLP-1 coverage for TFL, beneficiaries who met stringent prior-authorization criteria including documented comorbid conditions such as hypertension, sleep apnea, or metabolic dysfunction could be approved for GLP-1 medications
2026 Advanced Body & Laser Center
In August 2025, accelerated approval was granted for treating noncirrhotic MASH with F2F3 fibrosis, contingent on confirmatory ESSENCE outcomes
Lactate regulates pathological cardiac hypertrophy via histone lactylation modification
*A complete protein contains all eight essential amino acids